Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 21.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 465,317 shares of the biopharmaceutical company’s stock after purchasing an additional 83,050 shares during the period. Geode Capital Management LLC owned 1.07% of Abeona Therapeutics worth $2,942,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Rosalind Advisors Inc. increased its stake in shares of Abeona Therapeutics by 4.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after acquiring an additional 82,000 shares during the last quarter. Western Standard LLC raised its holdings in shares of Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after purchasing an additional 110,998 shares in the last quarter. Citigroup Inc. increased its stake in Abeona Therapeutics by 10.1% in the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after purchasing an additional 56,332 shares during the last quarter. Renaissance Technologies LLC lifted its position in Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after acquiring an additional 429,456 shares during the last quarter. Finally, Simplify Asset Management Inc. acquired a new stake in shares of Abeona Therapeutics during the second quarter worth about $1,732,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ABEO has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research report on Monday, November 25th. Finally, StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 31st.

Abeona Therapeutics Stock Performance

NASDAQ ABEO opened at $6.00 on Wednesday. Abeona Therapeutics Inc has a 52-week low of $3.05 and a 52-week high of $9.01. The firm has a 50-day moving average price of $5.99 and a 200 day moving average price of $5.64. The stock has a market capitalization of $260.83 million, a P/E ratio of -2.23 and a beta of 1.46. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.